604813-08-3

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-N-ISOPROPYL-PYRIDINE-2-CARBOXAMIDE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its ability to inhibit enzymes and biological processes makes it a valuable component in the development of drugs that target specific pathways or mechanisms in the body, contributing to the treatment or management of various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical industry, 4-CHLORO-N-ISOPROPYL-PYRIDINE-2-CARBOXAMIDE is utilized as a precursor in the production of pesticides. Its capacity to interfere with biological processes in pests and weeds allows for the creation of effective crop protection agents, enhancing agricultural productivity and crop yield by reducing damage from pests and diseases.
Used in Medicinal Chemistry Research:
4-CHLORO-N-ISOPROPYL-PYRIDINE-2-CARBOXAMIDE is employed as a research tool in medicinal chemistry. Its unique properties and reactivity make it suitable for exploring new chemical entities and potential drug candidates, advancing the understanding of molecular interactions and the development of novel therapeutic agents.
Used in Crop Protection Research:
4-CHLORO-N-ISOPROPYL-PYRIDINE-2-CARBOXAMIDE is also used in research within the field of crop protection. It aids in the discovery and optimization of new agrochemicals, enhancing the effectiveness of pest and disease control strategies in agriculture, and supporting sustainable farming practices.

InChI:InChI=1/C9H11ClN2O/c1-6(2)12-9(13)8-5-7(10)3-4-11-8/h3-6H,1-2H3,(H,12,13)

Upstream product

• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 75-31-0 isopropylamine 
• 98-98-6 2-Picolinic acid 
• 51727-15-2 4-chloropicolinoyl chloride hydrochloride 
• 24484-93-3 4-Chloro-pyridine-2-carboxylic acid methyl ester 

Downstream Products

• 1412891-43-0 4-(3-(3-(4-chlorophenyl)thioureido)phenoxy)-N-isopropylpicolinamide 
• 1412891-61-2 N-isopropyl-4-(3-(3-(4-(trifluoromethoxy)phenyl)thioureido)phenoxy)picolinamide 
• 1412891-64-5 4-(3-aminophenoxy)-N-isopropylpicolinamide 

Relevant academic research and scientific papers

Styryl pyridine compound containing pyridine structure, preparation method and application of styryl pyridine compound in preparation of antitumor drugs (by machine translation)

The invention belongs to the field, and particularly relates to a styryl pyridine compound containing a pyridine structure, a preparation method and an application of the styryl pyridine compound in preparation of anti-tumor drugs, wherein the compound is a compound as shown in the formula I. The compound of the general formula I has good inhibitory activity on non-small cell lung cancer A549 and liver cancer cell HepepepG2, can be used for preparing antitumor drugs, and is especially suitable for cancers, kidney cancer, lung cancer, thyroid cancer, colon cancer and other tumors. (by machine translation)

Discovery of novel picolinamide-based derivatives as novel VEGFR-2 kinase inhibitors: Synthesis,: in vitro biological evaluation and molecular docking

Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a crucial role in tumor angiogenesis, and inhibition of the VEGFR-2 signaling pathway has emerged as an attractive target for cancer therapy. In our effort, a novel series of picolinamide-based derivatives were designed and synthesized as potent and effective VEGFR-2 inhibitors. All the newly prepared compounds were evaluated in vitro for their antiproliferative activity against A549 and HepG2 cell lines. Among the new compounds, 8j and 8l exhibited better activity against both A549 and HepG2 cell lines. Molecular docking was performed to investigate the binding capacity and binding mode with VEGFR-2 (PDB code: 4ASD).

The structure of the amine-containing thiourea compound and its preparation method and application

A disclosed thiourea compounds containing an arylamine structure comprises compounds of a general formula I and pharmaceutically acceptable salts. In the general formula I shown in the specification, R1 is selected from H, C1-C8 alkyl, halogens, -CF3, -OCF3, -NO2, -CN, R2O-, -SO2NH2, -NHSO2R3, -NR4R5, -CONR6R7, -COOR8, R9CO- and disubstituted and trisubstituted combinations thereof, R2, R3, R4, R5, R6, R7, R8 and R9 are respectively H or C1-C8 alkyl, L is selected from -NHR10, -NHOR11, -NR12R13, pyrrolidin-1-yl, 4-piperidyl and (4-methyl-1-piperazinyl)methylene, and R10, R11, R12 and R13 are respectively H, C1-C8 alkyl, cycloalkyl or aryl. The compounds have inhibiting effect on multiple tumor cell strains.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

Design, synthesis and biological activities of sorafenib derivatives as antitumor agents

A series of novel sorafenib derivatives, 9a-w, was designed and synthesized in high yields using various substituted anilines, and their antiproliferative activities against HCT116, PC-3 and MDA-MB-231 cell lines were also evaluated and described. All compounds exhibited potent antiproliferative activity against HCT116 and PC-3 cells with IC50 = 2.8-52.0 and 2.2-45.6 μM; compounds 9p and 9q demonstrated competitive antiproliferative activities to sorafenib against all three cancer cell lines, the cytotoxicity of compound 9r is more potent than that of sorafenib. Compounds (9g, 9p, 9q and 9r) were chosen for further evaluation of the anti-angiogenesis activity, and showed the inhibition of sprout formation from aortic ring ex vivo. The structures of all the newly synthesized compounds were determined by 1H NMR, 13C NMR and HRMS.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.